| Tagrisso (osimertinib) / AstraZeneca |
2015-005637-47: Optimalt tidspunkt for at skifte behandling fra Tarceva til Tagrisso. Optimalt tidspunkt for at skifte behandling fra Tarceva til Tagrisso. |
|
|
| Ongoing | 4 | 50 | Europe | AZD9291 40mg film coated tablets, AZD9291 80mg filmcoated tablets, AZD9291, Film-coated tablet, , Tagrisso, Tarceva | Department of Oncology, Aarhus University Hospital | Lung Cancer, Lung Cancer Lungekræft, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2018-003954-26: CYP3A4*22 genotype-guided dosing of TKIs in cancer patients: a new way of personalized therapy Op basis van CYP3A4*22 genotype doseren van tyrosine-kinase remmers bij patiënten met kanker: een nieuwe manier van gepersonaliseerde therapie. |
|
|
| Not yet recruiting | 4 | 198 | Europe | Film-coated tablet, Capsule, hard, Coated tablet, Tablet, Cabozantinib/Cabometyx, Cobimetinib/Cotellic, Dabrafenib/Tafinlar, Dasatinib/Sprycel, Erlotinib/Tarceva, Everolimus/Afinitor/Votubia, Imatinib, Lapatinib/Tyverb, Nilotinib/Tasigna, Olaparib/Lynparza, Palbociclib/Ibrance, Ponatinib/Iclusig, Regorafenib/Stivarga, Ruxolitinib/Jakavi, Sunitinib/Sutent, Pazopanib/Votrient, Cabozantinib/Cometriq, Olaparib?Lynparza, Brigatinib - Alunbrig, Encorafenib - Braftovi, Osimertinib/Tagrisso | Erasmus MC Cancer Institute, Erasmus MC | Patients diagnosed with a neoplasm and treated with a tyrosine kinase inhibitor which is mainly metabolised by CYP3A4. Patienten gediagnosticeerd met een maligniteit en behandeld met een tyrosine kinase inhibitor welke voornamelijk wordt gemetaboliseerd door CYP3A4., Patients diagnosed with cancer and treated with a TKI. Patienten gediagnosticeerd met kanker en behandeld met een TKI., Diseases [C] - Cancer [C04] | | | | |
2018-004290-28: Study to osimertinib treatment in patients with lung cancer. Onderzoek naar de behandeling met osimertinib bij patiënten met longkanker. |
|
|
| Not yet recruiting | 4 | 20 | Europe | Tablet, Tybost | | Non-small cell lung carcinoma Niet kleincellig longcarcinoom, Lung cancer Longkanker, Diseases [C] - Cancer [C04] | | | | |
2019-002197-31: AFAMOSI: Efficacy and safety of afatinib followed by osimertinib compared to osimertinib in patients with EGFRmutated/T790M Mutation negative non-squamous NSCLC. AFAMOSI: Wirksamkeit und Sicherheit von Afatinib gefolgt von Osimertinib verglichen mit Osimertinib bei Patienten mit EGFR-mutiertem/T790M-negativem nicht zu den Plattenepithelkarzinom-zählendem NSCLC. |
|
|
| Not yet recruiting | 4 | 126 | Europe | Film-coated tablet, Giotrif, Tagrisso | Universitätsmedizin Mainz, Interdisziplinäres Zentrum klinische Studien, Boehringer Ingelheim Pharma GmbH & Co KG | EGFR mutated non-squamous NSCLC EGFR-mutiertes nicht plattenepithelialen NSCLC, non-small cell lung Cancer (NSCLC) Nicht kleinzelliges Lungenkarzinom (NSCLC), Diseases [C] - Cancer [C04] | | | | |
2020-001879-33: Efficacy study of osimertinib in treatment-naïve patients with EGFR mutant NSCLC according to TP53 mutational status (TEMPLE-2) Studio sull’efficacia di Osimertinib in prima linea nei pazienti con NSCLC EGFR mutati sulla base dello stato mutazionale di TP53 (TEMPLE-2) |
|
|
| Not yet recruiting | 4 | 122 | Europe | Osimertinib, [Osimertinib], Tablet, TAGRISSO | FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE, ASTRAZENECA | Patients with EGFR mutant NSCLC according to TP53 mutational status Pazienti con NSCLC EGFR mutati sulla base dello stato mutazionale di TP53, Patients with EGFR mutant NSCLC according to TP53 mutational status Pazienti con NSCLC EGFR mutati sulla base dello stato mutazionale di TP53, Diseases [C] - Cancer [C04] | | | | |
2022-003460-24: Investigation of the tumor concentrations of the anticancer drug osimertinib in tumor resection material of patients with colorectal cancer. Onderzoek naar de tumorconcentraties van het antikankermedicijn osimertinib in tumor operatieweefsel van patienten met darmkanker. |
|
|
| Not yet recruiting | 4 | 10 | Europe | Tablet, Tagrisso | Radboud University Medical Center, Radboud University Medical Center | Colorectal cancer, Colorectal cancer, Diseases [C] - Cancer [C04] | | | | |
NCT04356118: Efficacy and Safety of Recombinant Human Endostatin in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis |
|
|
| Not yet recruiting | 4 | 30 | NA | Recombinant Human Endostatin, Endostatin, intrathcal methotrexate, Targeted drugs for non-small cell lung cancer | Hui Bu | Leptomeningeal Metastasis | 06/23 | 06/23 | | |
ChiCTR2100048089: An exploratory clinical study on the the correlation of efficacy and adverse reactions of anlotinib combined with osimertinib in the treatment of EGFR-positive advanced non-small cell lung cancer between blood concentration and population pharmacokinetics |
|
|
| Not yet recruiting | 4 | 72 | | Osimertinib therapy ;Osimertinib+anlotinib therapy | The Fifth Affiliated Hospital of Sun Yat-sen University; The Fifth Affiliated Hospital of Sun Yat-sen University, Self-raised | Non-small cell lung cancerNon | | | | |
TEMPLE-2, NCT05785208: Efficacy Study of Osimertinib in Treatment-naïve Patients With EGFR Mutant NSCLC According to TP53 Mutational Status. |
|
|
| Recruiting | 4 | 122 | Europe | Osimertinib | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Non Small Cell Lung Cancer | 02/24 | 10/25 | | |
ChiCTR2100042664: An open, single-arm clinical study of Bevacizumab with Ositinib in patients with EGFR-positive advanced Nonsquamous non-small cell lung cancer: |
|
|
| Recruiting | 4 | 30 | | Bevacizumab(15mg/kg,q3w) and Osimertinib(80mg,qd) | Taizhou First People's Hospital; Taizhou First People's Hospital, CSCO Qili Foundation | NSCLC | | | | |
GPS, NCT05219162: Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(). |
|
|
| Completed | 4 | 182 | RoW | Gene Profile explore | AstraZeneca | Advanced NSCLC | 05/24 | 05/24 | | |
ChiCTR2100046251: Evaluate the Safety and Efficacy of Almonertinib in the Treatment of Advanced NSCLC Patients With EGFR-Sensitive Mutations Who Are Safety Intolerant After Osimertinib Treatment: a Prospective, Multi-Center, Single-Arm Clinical Trial |
|
|
| Recruiting | 4 | 40 | | received 110 mg of Almonertinib orally once a day | Shanghai Chest Hospital; The Affiliated Tumor Hospital of Chongqing University, Sponsored by Jiangsu Hausen Pharmaceutical Group Co., Ltd. | Non-small-cell lung carcinoma | | | | |
NCT04413201: AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients With EGFRmutated/T790M Mutation Negative Nonsquamous NSCLC |
|
|
| Active, not recruiting | 4 | 34 | Europe | Afatinib, Osimertinib | Michael Hopp, Boehringer Ingelheim | Non-squamous NSCLC | 06/24 | 06/24 | | |
| Not yet recruiting | 4 | 200 | | Observe ;Osimertinib or observe | The Fourth People's Hospital of Kunming (Anning First People's Hospital); The Fourth People's Hospital of Kunming (Anning First People's Hospital), Project funding and self-funded | Non-small lung cancer | | | | |
SELECT-2, NCT04401059: Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study |
|
|
| Recruiting | 4 | 744 | RoW | Elemene plus first or third generation EGFR-TKIs, H10960114, H20010338, First or third generation EGFR-TKIs, Gefitinib(Iressa,YiRuiKe), Erlotinib(Tarceva), Icotinib(Kaimeina), Osimertinib(Tagrisso), Almonertinib, Furmonertinib, etc. | Tian Xie, LinkDoc Technology (Beijing) Co. Ltd. | Carcinoma, Non-Small-Cell Lung Cancer, Adenocarcinoma | 09/25 | 03/26 | | |
OSIBOOST-2, NCT05748093: Improving Osimertinib Exposure and Cost-effectiveness Using Pharmacokinetic Boosting With Cobicistat |
|
|
| Recruiting | 4 | 60 | Europe | Cobicistat, Tybost | Maastricht University Medical Center | Non-small Cell Lung Cancer | 06/26 | 09/26 | | |
| Active, not recruiting | 3 | 419 | Europe, Canada, Japan, US, RoW | Chemotherapy, Osimertinib, Platinum-based Doublet-Chemotherapy, Cross-over to Osimertinib | AstraZeneca | Anticancer Treatment | 04/16 | 12/23 | | |
|
|
|
|
| Active, not recruiting | 3 | 674 | Europe, Canada, Japan, US, RoW | AZD9291 80 mg/40 mg + placebo, Placebo Erlotinib 150/100mg, Placebo Tarceva 150/100 mg, Placebo Gefitinib 250 mg, Placebo Iressa 250 mg, Erlotinib 150/100 mg, Tarceva 150/100 mg, Gefitinib 250 mg, Iressa 250mg, Placebo AZD9291 80 mg/ 40 mg | AstraZeneca, Parexel | Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer | 06/17 | 01/25 | | |
|
|
|
|
|
|
|
CAURAL, NCT02454933: Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours |
|
|
| Completed | 3 | 29 | Canada, RoW | AZD9291, MEDI4736 | AstraZeneca | Locally Advanced or Metastatic EGFR T790M+ NSCLC | 08/17 | 06/23 | | |
|
|
RELAY, NCT02411448 / 2014-004824-22: A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC |
|
|
| Active, not recruiting | 3 | 545 | Europe, Canada, Japan, US, RoW | Ramucirumab, LY3009806, Placebo, Erlotinib, Gefitinib, Osimertinib | Eli Lilly and Company | Metastatic Non-Small Cell Lung Cancer | 01/19 | 12/24 | | |
|
|
|
|
ADAURA, NCT02511106 / 2015-000662-65: AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy. |
|
|
| Active, not recruiting | 3 | 682 | Europe, Canada, Japan, US, RoW | AZD9291 80 mg/40 mg, Placebo AZD9291 80 mg/40 mg, Open-label AZD9291 80 mg/40 mg | AstraZeneca | Stage IB-IIIA Non-small Cell Lung Carcinoma | 04/22 | 01/29 | | |
|
|
|
|
|
|
2019-003969-18: A study to evaluate Chemotherapy Plus Osimertinib against Chemotherapy Plus Placebo in patients with non-small cell lung cancer (NSCLC) |
|
|
| Not yet recruiting | 3 | 204 | Europe | Osimertinib 80 mg, Osimertinib 40 mg, Cisplatin, Carboplatin, Pemetrexed, AZD9291, Film-coated tablet, Concentrate for solution for infusion, Solution for infusion, Powder for concentrate for solution for infusion, TAGRISSO | AstraZeneca AB, ASTRAZENECA AB, AstraZeneca AB | Non-Small Cell Lung Cancer, EGFRm locally adv or metastatic Non-Small Cell Lung Cancer., Diseases [C] - Cancer [C04] | | | | |
2021-001825-33: A Clinical Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure |
|
|
| Not yet recruiting | 3 | 690 | Europe, RoW | Amivantamab, Lazertinib, JNJ-61186372, JNJ-73841937/YH-25448, Solution for infusion, Tablet | Janssen-Cilag International NV, JANSSEN CILAG INTERNATIONAL NV, Janssen Research and Development, Janssen Cilag SpA | Locally Advanced or Metastatic Non-Small Cell Lung Cancer, A specific type of lung cancer called "Non-Small Cell Lung Cancer", Diseases [C] - Cancer [C04] | | | | |
2021-004135-89: A late stage clinical trial to investigate the efficacy and safety of Osimertinib versus Placebo in patients with stage IA2-IA3 non-small cell lung cancer, following complete tumour resection. Ensayo clínico para investigar la eficacia y seguridad de Osimertinib versus Placebo en pacientes en estadío IA2-IA3 de cáncer de pulmón no microcítico, tras la resección completa del tumor. |
|
|
| Not yet recruiting | 3 | 380 | Europe | Osimertinib 40 mg, Osimertinib 80 mg, AZD9291, Film-coated tablet, Tagrisso | AstraZeneca AB, ASTRAZENECA AB, AstraZenecaAB | Stage IA2-IA3 non-small cell lung carcinoma, with EGFR mutation type (Ex19del, L858R), following complete tumour resection. Estadio IA2-IA3 de cáncer de pulmón no microcítico, positivo para la mutación de EGFR (Ex19del, L858R), tras la resección completa del tumor., Specific type of lung cancer called non-small cell lung cancer (NSCLC) stage IA2-IA3 with EGFR mutations positive after complete surgical removal of a tumour between 1 and 3 centimetres. Tipo específico de cáncer de pulmón no microcítico (CPNM) en estadío IA2-IA3 positivo para mutaciones de EGFR, tras la resección completa del tumor entre 1 y 3 centímetros., Diseases [C] - Cancer [C04] | | | | |
2021-006374-24: A clinical trial to compare the effectiveness of savolitinib plus osimertinib versus chemotherapy for the treatment of non-small cell lung cancer Un ensayo clínico para comparar la eficacia de savolitinib más osimertinib frente a la quimioterapia para el tratamiento del cáncer de pulmón no microcítico |
|
|
| Not yet recruiting | 3 | 324 | Europe | Savolitinib, osimertinib 80 mg, osimertinib 40 mg, Cisplatin, Carboplatin, Pemetrexed, AZD6094, HMPL-504, AZD9291, Tablet, Film-coated tablet, Concentrate for solution for infusion, TAGRISSO | AstraZeneca AB, ASTRAZENECA AB, AstraZeneca AB | EGFR Mutated, MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Cáncer de pulmón no microcítico localmente avanzado o metastásico con mutación EGFR y MET positivo, Non-Small Cell Lung Cancer Cáncer de pulmón no microcítico, Diseases [C] - Cancer [C04] | | | | |
2022-000525-25: A Clinical Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Compared with Intravenous Amivantamab or Amivantamab Subcutaneous On Body Delivery System in Patients with EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer After Progression on Osimertinib and Chemotherapy Uno studio clinico di lazertinib con amivantamab per via sottocutanea somministrato tramite iniezione manuale rispetto ad amivantamab per via endovenosa o ad amivantamab per via sottocutanea in pazienti con carcinoma polmonare non a piccole cellule avanzato o metastatico con mutazioni di EGFR dopo progressione durante il trattamento con osimertinib e chemioterapia |
|
|
| Ongoing | 3 | 640 | Europe | Amivantamab (JNJ-61186372), Amivantamab (JNJ-61186372) co-formulated with recombinant human hyaluronidase (rHuPH20), Amivantamab JNJ-61186372 co-formulated with recombinant human hyaluronidase (rHuPH20) OBDS, Lazertinib mesylate monohydrate, [JNJ-61186372], [JNJ-73841937-ZCY/YH25448AM], Concentrate for solution for infusion, Concentrate for solution for injection/infusion, Film-coated tablet | JANSSEN CILAG INTERNATIONAL NV, Janssen-Cilag International NV, Janssen Research & Development, LLC | EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer carcinoma polmonare non a piccole cellule avanzato o metastatico con mutazioni di EGFR, A specific type of lung cancer called "Non-Small Cell Lung Cancer" carcinoma polmonare non a piccole cellule, Diseases [C] - Cancer [C04] | | | | |
TOP, NCT04695925: Phase III Study Comparing Osimertinib Monotherapy to Combination Therapy With Osimertinib,Carboplatin and Pemetrexed for Untreated Patients With Advanced Non-squamous Non-Small Cell Lung Cancer With Concurrent EGFR and TP53 Mutations |
|
|
| Not yet recruiting | 3 | 291 | RoW | Osimertinib 80 MG [Tagrisso], Pemetrexed 500 MG Injection, Carboplatin | Li Zhang, MD | Non-small Cell Carcinoma, EGFR Gene Mutation | 09/22 | 12/23 | | |
FLAURA2, NCT04035486 / 2019-000650-61: A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer |
|
|
| Active, not recruiting | 3 | 587 | Europe, Canada, Japan, US, RoW | Osimertinib, AZD9291, Pemetrexed/Carboplatin, Pemetrexed/Cisplatin | AstraZeneca | Non-Small Cell Lung Cancer | 04/23 | 06/26 | | |
|
|
MARIPOSA-2, NCT04988295: A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure |
|
|
| Active, not recruiting | 3 | 776 | Europe, Canada, Japan, US, RoW | Lazertinib, JNJ-73841937, YH-25448, Amivantamab, JNJ-61186372, Pemetrexed, Carboplatin | Janssen Research & Development, LLC | Carcinoma, Non-Small-Cell Lung | 07/23 | 12/25 | | |
TREBLE, NCT05493501: Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer |
|
|
| Terminated | 3 | 8 | US | Aumolertinib monotherapy, EQ143, HS-10296, Osimertinib monotherapy, Tagrisso, Pemetrexed, Alimta, Cisplatin, Carboplatin, Paclitaxel, Taxol, Nab paclitaxel, Abraxane, Albumin-bound paclitaxel, Gemcitabine, Gemzar | EQRx International, Inc. | NSCLC | 08/23 | 08/23 | | |
PALOMA-3, NCT05388669 / 2022-000525-25: A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer |
|
|
| Active, not recruiting | 3 | 418 | Europe, Canada, Japan, US, RoW | Lazertinib, JNJ-73841937, YH25448, Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF), JNJ-61186372, Amivantamab Intravenous | Janssen Research & Development, LLC, Janssen Research & Development, LLC | Advanced or Metastatic Non-small Cell Lung Cancer | 01/24 | 01/25 | | |
NCT05104281: Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 60 | RoW | osimertinib oral and bevazizumab intravenously, bevacizumab, osimertinib | Qingdao Central Hospital | Carcinoma, Non-Small-Cell Lung | 12/23 | 12/24 | | |
LAURA, NCT03521154 / 2018-001061-16: A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer |
|
|
| Active, not recruiting | 3 | 216 | Europe, Japan, US, RoW | Osimertinib 80mg/40mg, Placebo Osimertinib 80mg/40mg | AstraZeneca | Non Small Cell Lung Cancer (Stage III) | 01/24 | 06/26 | | |
|
|
NCT06323148: Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022) |
|
|
| Not yet recruiting | 3 | 226 | NA | Osimertinib, No adjuvant therapy | Fudan University | Lung Cancer, EGFR Gene Mutation, Minimal Residual Disease | 03/26 | 03/29 | | |
NCT06380348: JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations |
|
|
| Not yet recruiting | 3 | 398 | NA | JMT101 Injection, Osimertinib tablet, Cisplatin injection, Pemetrexed injection | Shanghai JMT-Bio Inc. | Local Advanced or Metastatic NSCLC | 03/27 | 03/28 | | |
TROPION-Lung14, NCT06350097: Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 582 | Europe, RoW | Osimertinib, Osimertinib: AZD9291, Datopotamab Deruxtecan: Dato-DXd, Datopotamab Deruxtecan | AstraZeneca, Daiichi Sankyo | Non-small Cell Lung Cancer | 03/28 | 05/32 | | |
| Active, not recruiting | 3 | 1074 | Europe, Canada, Japan, US, RoW | Amivantamab, JNJ-61186372, Osimertinib, Lazertinib, JNJ-73841937 and YH-25448, Placebo | Janssen Research & Development, LLC | Carcinoma, Non-Small-Cell Lung | 04/24 | 06/27 | | |
|
ATTACK, NCT04870190: Almonertinib Versus Osimertinib in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases |
|
|
| Not yet recruiting | 3 | 232 | NA | Almonertinib, HS-10296, Osimertinib, Teresa, AZD9291 | Shanghai Chest Hospital | NSCLC | 06/24 | 06/24 | | |
COMPEL, NCT04765059: A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC) |
|
|
| Active, not recruiting | 3 | 98 | Europe, US, RoW | Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin, Placebo for osimertinib (AZD9291) pemetrexed cisplatin or carboplatin | AstraZeneca, Parexel | Non-small Cell Lung Cancer | 12/24 | 12/24 | | |
NeoADAURA, NCT04351555 / 2020-000058-89: A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 328 | Europe, Canada, Japan, US, RoW | Osimertinib, AZD9291; TAGRISSO, Cisplatin, Carboplatin, Placebo, Pemetrexed | AstraZeneca | Non-Small Cell Lung Cancer | 07/24 | 06/29 | | |
|
TROPION Lung15, NCT06417814: A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer |
|
|
| Not yet recruiting | 3 | 630 | NA | Dato-DXd, DS-1062a, Osimertinib, Tagrisso, AZD9291, Pemetrexed, Carboplatin, Cisplatin | AstraZeneca, Daiichi Sankyo | Metastatic Non-small Cell Lung Cancer | 09/26 | 02/28 | | |
SACHI, NCT05015608: Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification |
|
|
| Recruiting | 3 | 250 | RoW | Savolitinib + Osimertinib, Pemetrexed + Cisplatin /Carboplatin | Hutchison Medipharma Limited | Non-small Cell Lung Cancer | 09/24 | 11/24 | | |
SANOVO, NCT05009836: Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC |
|
|
| Recruiting | 3 | 320 | RoW | Savolitinib, HMPL-504, Placebo | Hutchison Medipharma Limited | Non-small Cell Lung Cancer | 11/24 | 01/25 | | |
ChiCTR2100045604: A randomized, open-label, multicenter, phase III study of osimertinib plus chemotherapy versus osimertinib monotherapy in EGFR active mutant NSCLC with concomitant mutation |
|
|
| Recruiting | 3 | 296 | | osimertinib ;osimertinib plus chemotherapy | Affiliated Tumor Hospital of Guangxi Medical University; Affiliated Tumor Hospital of Guangxi Medical University, Beijing Xisike Clinical Oncology Research Foundation | Lung cancer | | | | |
ROSY-T, NCT05629234: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) |
|
|
| Active, not recruiting | 3 | 37 | Europe, RoW | Osimertinib, TAGRISSO | AstraZeneca, Parexel | Cancer | 02/25 | 02/25 | | |
FLETEO, NCT05382728: Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 680 | RoW | TY-9591, TY-9591 Tablets, placebo Osimertinib, placebo Tagrisso, Osimertinib, Tagrisso, placebo TY-9591, placebo TY-9591 Tablets | TYK Medicines, Inc | NSCLC, EGFR Activating Mutation | 05/25 | 12/27 | | |
SAFFRON, NCT05261399: Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment |
|
|
| Recruiting | 3 | 324 | Europe, Canada, Japan, US, RoW | Savolitinib, AZD6094, HMPL-504, volitinib, Osimertinib, AZD9291, Tagrisso, Pemetrexed, NAP, Cisplatin, Carboplatin | AstraZeneca | Carcinoma, Non-Small-Cell Lung | 06/25 | 12/26 | | |
PACIFIC-4, NCT03833154 / 2018-002572-41: Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation |
|
|
| Recruiting | 3 | 690 | Europe, Canada, Japan, US, RoW | Durvalumab, MEDI4736, Placebo, Osimertinib (single-arm, open-label) | AstraZeneca | Carcinoma, Non-Small-Cell Lung | 03/26 | 04/28 | | |
|
|
NCT04181060: Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer |
|
|
| Recruiting | 3 | 300 | US | Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, CT-P16, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Osimertinib, AZD-9291, AZD9291, Mereletinib | National Cancer Institute (NCI) | Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8 | 12/26 | 12/26 | | |
ADAURA2, NCT05120349: A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection |
|
|
| Recruiting | 3 | 380 | Europe, Canada, Japan, US, RoW | Osimertinib, AZD9291; TAGRISSO, Placebo | AstraZeneca | Non-Small Cell Lung Cancer | 08/27 | 11/32 | | |
M22-142, NCT06093503: Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein |
|
|
| Withdrawn | 3 | 250 | NA | Telisotuzumab Vedotin, ABBV-399, Osimertinib, Cisplatin, Carboplatin, Pemetrexed | AbbVie | Non-Small Cell Lung Cancer | 04/28 | 04/28 | | |
NCT05020769: SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer. |
|
|
| Recruiting | 2/3 | 14 | RoW | SI-B001, Osimertinib | Sichuan Baili Pharmaceutical Co., Ltd. | Non-small Cell Lung Cancer | 08/24 | 08/24 | | |
CTR20212842: Phase II clinical study of the safety and efficacy of JMT101 combined with osimertinib in patients with stage IIIb-IV non-small cell lung cancer with EGFR mutations |
|
|
| Not yet recruiting | 2 | 296 | China | Tagrisso (osimertinib) - AstraZeneca | Shanghai Jinmante Biotechnology Co., Ltd. | EGFR mutated stage IIIb-IV non-small cell lung cancer | | | | |
OSIRAM-1, jRCT2080224085: A Randomized Phase II Study of Osimertinib + Ramucirumab Versus Osimertinib as First-Line Chemotherapy for EGFR Mutation-Positive Non-Squamous Cell Non-Small Cell Lung Cancer |
|
|
| Completed | 2 | 120 | Japan | Tagrisso (osimertinib) - AstraZeneca, Cyramza (ramucirumab) - Eli Lilly | Kanagawa Prefectural Cancer Center | EGFR mutation-positive non-squamous non-small-cell lung cancer | | | | |
YAMATO, jRCTs031200021: A Randomized Phase II Study of Switching Therapy from Afatinib to Osimertinib in the Initial Treatment of Epidermal Growth Factor Receptor (EGFR) Gene Mutation-Positive Non-Squamous Non-Small Cell Lung Cancer (TORG1939/WJOG12919L) |
|
|
| Completed | 2 | 110 | Japan | Gilotrif (afatinib) - Boehringer Ingelheim | Kansai Medical University Hospital | Lung cancer | | | | |
TORG2040, jRCTs041200100: First-Line Osimertinib for Poor Performance Status Patients with EGFR Mutant Non-Small Cell Lung Cancer |
|
|
| Active, not recruiting | 2 | 30 | Japan | Tagrisso (osimertinib) - AstraZeneca | Kitasato University Hospital | Non-small cell lung cancer | | | | |
ACTRN12623000552684: OCEANiC: A Phase II, Open-label, Multi-centre Clinical Trial of Osimertinib With or Without Adjuvant Chemotherapy Guided by Tumour NGS Co-mutation Status and ctDNA Detection in Patients With
Stage IIA-IIIA EGFR-Mutant Non Small Cell Lung Cancer Following Complete Surgical Resection |
|
|
| Recruiting | 2 | 100 | | | The University of Sydney, AstraZeneca Australia Pty Ltd | EGFR-Mutant Non Small Cell Lung Cancer Following Complete Surgical Resection | | | | |
| Completed | 2 | 210 | Europe, Canada, Japan, US, RoW | AZD9291 | AstraZeneca | Non Small Cell Lung Cancer | 05/15 | 11/23 | | |
NCT06303167: Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E) |
|
|
| Active, not recruiting | 2 | 19 | NA | Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Echocardiography, EC, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Osimertinib, AZD-9291, AZD9291, Mereletinib, Radiologic Examination, Radiologic Evaluation, Radiologic Exam | National Cancer Institute (NCI) | Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma | 02/23 | 12/25 | | |
2015-001970-16: this trial is finalized to evaluate the tolerability and the quality of life in patients with Lung cancer who take AZD9291 Questa sperimentazione ¿ finalizzata a valutare la tollerabilit¿ e l'impatto sulla qualit¿ della vita dei pazienti affetti da tumore polmonare che assumono AZD9291 |
|
|
| Ongoing | 2 | 32 | Europe | AZD9291, Capsule, hard | ASSOCIAZIONE PIEMONTESE DI ONCOLOGIA TORACICA (APOT), AstraZeneca | Subjects with EGFRm+/T790M, locally advanced or metastatic NSCLC who have progressed following prior therapy with an approved EGFR-TKI Pazienti con EGFRm+/T790M, affetti da NSCLC localmente avanzato o metastatico la cui malattia ¿ in progressione dopo precedente terapia con EGFR-TKI, lung cancer Patients progressed after a previous chemotherapy Pazienti affetti da tumore al polmone in progressione dopo una precedente terapia, Diseases [C] - Cancer [C04] | | | | |
| Active, not recruiting | 2 | 171 | RoW | AZD9291 | AstraZeneca | Non-Small Cell Lung Cancer | 03/16 | 12/22 | | |
|
2014-000814-73: National Lung Matrix: Multi-drug Phase II trial in Non-Small Cell Lung Cancer |
|
|
| Not yet recruiting | 2 | 620 | Europe | Palbociclib, Xalkori, Selumetinib, Docetaxel, Taxotere, Taxceus, Sitravatinib, AZD4547, AZD2014, PD 0332991, PF-02341066, AZD6244, ARRY 142886, MEDI4736, AZD5363, AZD9291, MGCD516, Tablet, Capsule, Concentrate for solution for infusion, Lyophilisate for solution for infusion, Xalkori, Docetaxel, Taxotere, Taxceus | University of Birmingham, AstraZeneca, Pfizer, Cancer Research UK | Metastatic or locally advanced non-small cell lung cancer (NSCLC), Commonest form of lung cancer, non-small cell lung cancer (NSCLC), Diseases [C] - Cancer [C04] | | | | |
2016-002555-17: Phase II Study evaluating the effect of osimertinib in patients with non-small cell lung cancer locally advanced or metastatic with T790M resistance mutation "not evaluable or unknown", undergoing chemotherapy after failure of treatment with tyrosine kinase inhibitors. Studio di fase II di valutazione dell'effetto di osimertinib in pazienti affetti da carcinoma polmonare non a piccole cellule localmente avanzato o metastatico con mutazione di resistenza T790M ¿non valutabile o non nota¿, sottoposti a chemioterapia dopo fallimento del trattamento con inibitori delle tirosinchinasi. |
|
|
| Not yet recruiting | 2 | 90 | Europe | osimertinib, AZD9291, Film-coated tablet, Tagrisso | AZIENDA OSPEDALIERO - UNIVERSITARIA "POLICLINICO - VITTORIO EMANUELE", AstraZeneca | Locally Advanced or Metastatic EGFR mutated, "T790M undetectable or unknown" Non Small Cell Lung Cancer (Stage IIIB-IV) Carcinoma polmonare non a piccole cellule localmente avanzato o metastatico (stadio IIIB-IV) EGFR mutato, con mutazione T790M ¿non valutabile o non nota¿, Locally Advanced or Metastatic Lung Cancer with undetectable or unknown tyrosin-kinase resistance mutation. Tumore al polmone localmente avanzato o metastatico con mutazione di resistenza agli inibitori delle tirosinchinasi non valutabile o non nota., Diseases [C] - Cancer [C04] | | | | |
2016-001834-82: Clinical trial to assess the feasibility and the activity of osimertinib on patients with non small cell lung cancer |
|
|
| Ongoing | 2 | 156 | Europe | osimertinib, gefitinib, AZD9291, ZD1839, Film-coated tablet, Tablet, Tagrisso, Iressa | European Organisation for Research and Treatment of Cancer (EORTC), EORTC, Astra Zeneca | NSCLC patients, Lung cancer called "non small cell lung cancer (NSCLC)", Diseases [C] - Cancer [C04] | | | | |
2018-001863-21: Novel treatment for people with lung cancer harbouring a specific mutation |
|
|
| Not yet recruiting | 2 | 120 | Europe | Tagrisso 40 mg film-coated tablet, Tagrisso 80 mg film-coated tablet, Tablet, Tagrisso | Vestre Viken Hospital Trust, Vestre Viken Hospital Trust | Lung Cancer, Lung Cancer, Diseases [C] - Cancer [C04] | | | | |
2018-003218-42: MEchanisms of resitance in EGFR mutated nonpretreated advanced Lung cancer Receiving OSimErtib Mécanismes de résistance chez des patients avec un cancer du poumon avancé non prétraité, EGFR muté, recevant un traitement par OSIMERTINIB |
|
|
| Not yet recruiting | 2 | 66 | Europe | osimertinib, Film-coated tablet, Tagrisso 40mg, Tagrisso 80mg | CHU de Nantes, AstraZeneca | Locally advanced or metastatic Non-small-cell lung carcinoma Cancer du poumon non à petites cellules localement avancé ou métastatique, Non-small-cell lung carcinoma Cancer du poumon non à petites cellules, Diseases [C] - Cancer [C04] | | | | |
2017-004734-28: Patients on osimertinib with EGFR mutation exon 20, non-T790M in lung cancer. The position-20 trial. |
|
|
| Not yet recruiting | 2 | 15 | Europe | osimertinib, AZD9291, Tablet, Tagrisso | University Medical Center Groningen, University Medical Center Groningen | Patients on osimertinib with EGFR mutation exon 20, non-T790M in lung cancer. The position-20 trial., Patients on osimertinib with EGFR mutation exon 20, non-T790M in lung cancer. The position-20 trial., Diseases [C] - Cancer [C04] | | | | |
2018-003012-51: Osimertinib plus savolitinib in patients with EGFRm+/MET+ non small cell lung cancer following prior osimertinib |
|
|
| Not yet recruiting | 2 | 360 | Europe | osimertinib 80 mg, osimertinib 40 mg, Savolitinib, AZD9291, AZD6094, Film-coated tablet, Coated tablet, TAGRISSO | AstraZeneca AB, ASTRAZENECA AB, AstraZeneca AB | EGFRm+ and MET+, Locally Advanced or Metastatic Non Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Diseases [C] - Cancer [C04] | | | | |
ACTRN12617000720314: Phase 2 trial of alternating osimertinib with gefitinib in patients with EGFR-T790M mutation positive advanced non-small cell lung cancer |
|
|
| Completed | 2 | 50 | | | University of Sydney, AstraZeneca | EGFR-T790M mutation positive advanced non-small cell lung cancer | | | | |
ChiCTR1800016544: A Open-label, Double arms, pilot Phase II study in single centre to Evaluate the Efficacy of early conversion to Osimertinib Versus continue to First-generation EGFR-TKIs in patients with acquired T790M mutation positive in EGFR-mutant NSCLC patients after Treating with First-generation EGFR-TKIs |
|
|
| Not yet recruiting | 2 | 100 | | Osimertinib ;First-generation EGFR-TKIs/Osimertinib | Hangzhou Cancer Hospital; Hangzhou Cancer Hospital, Shuwen Biotech Co. Ltd | Non-Small Cell Lung Cancer | | | | |
NCT03257124: Study of AZD9291 in NSCLC Patients Harboring T790M Mutation Who Failed EGFR TKI and With Brain and/or LMS |
|
|
| Active, not recruiting | 2 | 80 | RoW | AZD9291, Osimertinib | Samsung Medical Center | Non-Small Cell Lung Cancer With EGFR T790M Mutation, With Brain and/or Leptomeningeal Metastasis, Failed Tyrosine Kinase Inhibitors | 08/19 | 12/21 | | |
2019-001316-38: A clinical trial on an individualized treatment strategy for patients with metastatic non-clear cell kidney cancer Et lægemiddelforsøg af en individualiseret behandlingsstrategi til patienter med undertypen non-clear celle nyrekræft, som har spredt sig |
|
|
| Not yet recruiting | 2 | 30 | Europe | Capsule, hard, Film-coated tablet, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Tafinlar, Tarceva, Keytruda, Mekinist, Alecensa, Lynparza, Kadcyla, Cabometyx, Xalkori, Ibrance, Tagrisso, Glivec, Sutent, Opdivo | Department of Oncology, Herlev University Hospital, Region Hovedstaden, Roche Denmark | Patients with metastatic non-clear cell or 100% sarcomatoid renal cell carcinoma referred for first line treatment at the Department of Oncology, Herlev University Hospital Patienter med metastatisk non-clear cell eller 100% sarkomatoid nyrekræft, som henvises med henblik på første linje behandling på onkologisk afdeling, Herlev Hospital, Patients with metastatic kidney cancer with the subtype non-clear cell or 100% sarcomatoid referred for first line treatment at the Department of Oncology, Herlev University Hospital Patienter med undertypen non-clear cell eller 100% sarkomatoid nyrekræft, som har spredt sig og henvises for at påbegynde den første medicinske kræftbehandling på onkologisk afdeling, Herlev Hospital, Diseases [C] - Cancer [C04] | | | | |
2019-001538-33: This study will look at whether the study drug Tepotinib works to stop the re-growth of your lung cancer. The study drug will be used in combination with an approved lung cancer medication called osimertinib, which is an EGFR inhibitor. This is a Phase II study, which means that the study drug has already been tested in a small number of people in previous clinical research studies. Only patient who have progressed on first-line osimertinib due to MET amplification will be enrolled in the study |
|
|
| Not yet recruiting | 2 | 122 | Europe | tepotinib, MSC2156119J, Film-coated tablet, TAGRISSO | Merck Healthcare KGaA, MERCK HEALTHCARE KGaA, Merck Healthcare KGaA | Locally advanced or metastatic NSCLC histology (confirmed by either histology or cytology) with documented activating mutation of the EGFR receptor including T790M statusResistance on previous first line osimertinib, Lung Cancer, Diseases [C] - Cancer [C04] | | | | |
2019-002805-23: Study of osimertinib in patients with a lung cancer with Brain or Leptomeningeal metastases with harboring a EGFR mutation |
|
|
| Not yet recruiting | 2 | 112 | Europe | Osimertinib, AZD9291, Film-coated tablet, Tagrisso | IFCT, IFCT, AstraZeneca | EGFR-mutated Non-small cell lung cancer (NSCLC) with Brain or Leptomeningeal metastases, lung cancer with Brain or Leptomeningeal metastases with harboring a EGFR mutation, Diseases [C] - Cancer [C04] | | | | |
ChiCTR1800019710: Osimertinib combined with Pemetrexed compared to Osimertinib monotherapy in the treatment of patients EGFR T790M–Positive Lung Cancer: a prospective, phase II randomized controlled trial |
|
|
| Not yet recruiting | 2 | 100 | | Pemetrexed | Fujian Tumor Hospital; Fujian Tumor hospital, Patients at his own expense | adenocarcinoma lung cancer | | | | |
ChiCTR1800016948: A multicenter, open-label, single arm pilot study: Osimertinib as neoadjuvant treatment for resectable stage II-IIIB EGFR mutant lung adenocarcinoma (NEOS) |
|
|
| Recruiting | 2 | 40 | | neoadjuvant osimertinib | Thoracic Surgery II, Beijing Cancer Hospital; China anti-cancer association, AstraZeneca Pharmaceutical Company | Lung cancer | | | | |
JMT101-CSP-005, NCT06391944: JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations |
|
|
| Active, not recruiting | 2 | 161 | RoW | JMT101 Injection, Osimertinib tablet | Shanghai JMT-Bio Inc. | Local Advanced or Metastatic NSCLC, Harboring EGFR Common Mutation | 05/23 | 11/26 | | |
2020-003512-27: Radiation during Osimertinib Treatment: a Safety and Efficacy Cohort Study |
|
|
| Not yet recruiting | 2 | 60 | Europe | Osimertinib, Film-coated tablet, Osimertinib | AIO-Studien-gGmbH, AstraZeneca GmbH | Patients with EGFR-mutation positive NSCLCThe target population will comprise 3 parallel cohorts, for each of which a minimum of 10 subjects is planned to be enrolled:1. Irradiation of bone, solid organ (non-lung, non-brain) or soft-tissue metastases2. Irradiation of brain metastases (initial lesion size < 3 cm)3. Irradiation of lung lesions (primary tumor or metastases, lesion size < 5 cm), Patients with non-small lung cancer patients will be classified in 3 cohorts; Irradiation of 1. bone, solid organ or soft-tissue metastases2. brain metastases 3. lung lesions, Diseases [C] - Cancer [C04] | | | | |
2020-004114-35: A clinical study exploring the effect of osimertinib and radiation therapy, in people with newly diagnosed non-small cell lung cancer (NSCLC) that has spread to a few other parts of the body and shows a change (mutation) in the EGFR gene. Un estudio clínico que explora el efecto del osimertinib y la radioterapia en personas con cáncer de pulmón de células no pequeñas (CPCNP) recién diagnosticado que se ha diseminado a algunas otras partes del cuerpo y muestra un cambio (mutación) en el gen EGFR. |
|
|
| Not yet recruiting | 2 | 60 | Europe | Osimertinib, [AZD9291], Tablet, Tagrisso | European Thoracic Oncology Platform (ETOP), EUROPEAN THORACIC ONCOLOGY PLATFORM, ETOP IBCSG Partners Foundation, AstraZeneca AG Switzerland | Treatment naïve patients with synchronous, oligo-metastatic (primary tumour and maximum 5 metastases) EGFR-mutant (exon 19 deletion or exon 21 L858R) NSCLC with or without T790M resistance mutation Pacientes sin tratamiento previo con NSCLC sincrónico, oligo-metastásico (tumor primario y un máximo de 5 metástasis) mutante EGFR (deleción del exón 19 o exón 21 L858R) con o sin mutación de resistencia T790M, newly diagnosed non-small cell lung cancer (NSCLC) that has spread to a few other parts of the body and shows a change (mutation) in the EGFR gene. Cáncer de pulmón de células no pequeñas (CPCNP) recién diagnosticado que se ha diseminado a algunas otras partes del cuerpo y muestra un cambio (mutación) en el gen EGFR., Diseases [C] - Cancer [C04] | | | | |
2021-003305-21: First-line Osimertinib plus Consolidation Radiotherapy compared with Osimertinib alone in oligometastatic NSCLC EGFR mutated patients: the randomized phase II OCRa trial GOIRC-06-2019 Studio randomizzato di fase II di confronto tra Osimertinib in associazione alla radioterapia di consolidamento e Osimertinib da solo in pazienti con tumore polmonare non a piccole cellule (NSCLC) in stadio oligometastatico e con mutazione a carico di EGFR: studio OCRa- GOIRC-06-2019 |
|
|
| Not yet recruiting | 2 | 80 | Europe | TAGRISSO 80 mg, TAGRISSO 40 mg, [TAGRISSO 80 mg], [TAGRISSO 40 mg], Tablet, TAGRISSO | GRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC), AstraZeneca S.p.A. | EGFR mutated NSCLC patients with oligometastatic disease pazienti con NSCLC EGFR mutati e in stadio oligometastatico, patients NonSmal Cell Lung Cancer, EGFR mutated oligometastatic disease pazienti con carcinoma polmonare non a piccole cellule EGFR mutati e in stadio oligometastatico, Diseases [C] - Cancer [C04] | | | | |
NCT04316351: Efficacy and Safety of Toripalimab (JS001) Combined With Pemetrexed and Anlotinib for Patients With T790M Positive Non-Small Cell Lung Cancer After Osimertinib Resistance |
|
|
| Recruiting | 2 | 60 | RoW | Toripalimab + Pemetrexed + Anlotinib, JS001 | Guangzhou Institute of Respiratory Disease, Shanghai Junshi Bioscience Co., Ltd. | IIIb/IV NSCLC With T790M Positive Mutations Failed to Osimertinib Therapy | 04/22 | 04/22 | | |
NCT05458726: Correlation Between Efficacy of Osimertinib and EGFR T790M Status and Ratio Via ddPCR in NSCLC |
|
|
| Recruiting | 2 | 80 | RoW | Osimertinib, paclitaxel, carboplatin, pemetrexed | Peking Union Medical College | EGFR T790M, Osimertinib, Non-small Cell Lung Cancer, ddPCR | 07/22 | 10/22 | | |
INDIGO, NCT04644432: Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma |
|
|
| Recruiting | 2 | 30 | Europe | Medication (A specification is listed under each arm), Patient reported outcomes measurement, PRO | Herlev and Gentofte Hospital | Metastatic Renal Cell Carcinoma, Kidney Neoplasm, Urologic Neoplasms, Urogenital Neoplasms | 09/22 | 09/22 | | |
ChiCTR2000036856: Treatment strategy of malignant pleural effusion in EGFR sensitive mutant lung cancer: a prospective, randomized controlled trial |
|
|
| Not yet recruiting | 2 | 200 | | Osimertinib alone ;Osimertinib combined with pleurodesis | Shanghai Chest hospital; Shanghai Chest hospital, Three year action plan for promoting clinical skills and clinical innovation in municipal hospitals (2020-2022) major clinical research projects | lung cancer | | | | |
NCT04517526: Efficacy and Safety of Platinum-based Chemotherapy + Bevacizumab + Durvalumab, and Salvage SBRT for IV Non-Small Cell Lung Cancer Patients With EGFR Mutations After Failure of First Line Osimertinib: A Multicenter, Prospective, Phase II Clinical Study |
|
|
| Not yet recruiting | 2 | 60 | RoW | pemetrexed，cisplatin/carboplatin，bevacizumab，durvalumab，SBRT | Shanghai Cancer Hospital, China | Lung Cancer Stage IV，EGFR-mutant，TKI，PD-L1，SBRT | 11/22 | 12/22 | | |
NCT04099836: Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib |
|
|
| Terminated | 2 | 7 | US | Atezolizumab, TECENTRI, Bevacizumab, Avastin | Duke University | Non Small Cell Lung Cancer | 11/22 | 06/23 | | |
NCT02824952: Neo-adjuvant Trial With AZD9291 in EGFRm+ Stage IIIA/B NSCLC |
|
|
| Recruiting | 2 | 40 | RoW | Tagrisso, AZD9291 | Shaare Zedek Medical Center, AstraZeneca | Lung Cancer, Non-small Cell | 12/22 | 12/22 | | |
| Terminated | 2 | 3 | RoW | osimertinib mesylate tablets and anlotinib hydrochloride capsules, TAGRISSO and FOCUS V | First Affiliated Hospital of Zhejiang University | Non Small Cell Lung Cancer | 12/22 | 02/23 | | |
CoC, NCT04606771: A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC |
|
|
| Active, not recruiting | 2 | 30 | US, RoW | Osimertinib + Savolitinib, Savolitinib + Placebo | AstraZeneca | Non-Small Cell Lung Cancer | 12/22 | 12/24 | | |
PIKACHU, NCT04322890: Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation |
|
|
| Recruiting | 2 | 6000 | RoW | Osimertinib, Erlotinib, Gefitinib, Furmonertinib, Almonertinib etc., Alectinib 150 MG, Lorlatinib, Alectinib, Brigatinib, Ceritinib etc., Crizotinib 250 MG, Entrectinib, Savolitinib, Crizotinib., Crizotinib, Chemotherapy, Pemetrexed, Cisplatin, Pralsetinib etc. | Hunan Province Tumor Hospital | Non Small Cell Lung Cancer, EGFR Gene Mutation, ALK Gene Mutation, ROS1 Gene Mutation, MET Gene Mutation | 12/26 | 12/27 | | |
NCT02736513: Intracranial Activity of AZD9291 (TAGRISSO) in Advanced EGFRm NSCLC Patients With Asymptomatic Brain Metastases |
|
|
| Active, not recruiting | 2 | 40 | RoW | AZD9291, TAGRISSO | Soroka University Medical Center | Lung Cancer | 12/22 | 12/22 | | |
NCT03433469: Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery |
|
|
| Active, not recruiting | 2 | 27 | US | Osimertinib, AZD-9291, Tagrisso, Therapeutic Conventional Surgery | University of California, San Francisco, AstraZeneca | Stage I Non-Small Cell Lung Cancer, Stage IA Non-Small Cell Lung Cancer, Stage IB Non-Small Cell Lung Cancer, Stage II Non-Small Cell Lung Cancer, Stage IIA Non-Small Cell Lung Cancer, Stage IIB Non-Small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer | 01/23 | 10/26 | | |
| Active, not recruiting | 2 | 156 | Europe, RoW | Osimertinib, AZD9291, Tagrisso, Gefitinib, Iressa | European Organisation for Research and Treatment of Cancer - EORTC, AstraZeneca | NSCLC | 02/23 | 12/27 | | |
2021-002337-42: A clinical study exploring the effect of amivantamab and lazertinib plus bevacizumab treatment, in people diagnosed with advanced non-small cell lung cancer (NSCLC) that shows a change (mutation) in the EGFR gene and has spread to other parts of the body during or after treatment with osimertinib or lazertinib. Un estudio clínico que explora el efecto del tratamiento con amivantamab y lazertinib más bevacizumab, en personas diagnosticadas con cáncer de pulmón de células no pequeñas (CPCNP) avanzado que muestra un cambio (mutación) en el gen EGFR y se ha diseminado a otras partes del cuerpo durante o después del tratamiento con osimertinib o lazertinib. |
|
|
| Ongoing | 2 | 60 | Europe | Amivantamab, Lazertinib, Concentrate for solution for infusion, Film-coated tablet, Zirabev | ETOP IBCSG Partners Foundation, Janssen Pharmaceutica | patients with EGFR-mutant advanced NSCLC with progression on previous third generation EGFR TKI Pacientes con NSCLC avanzado con mutación de EGFR con progresión en TKI de EGFR de tercera generación anterior, Patients with non-small cell lung cancer that:• Has a change (mutation) in a gene called EGFR• Has spread to other parts of the body during, or after treatment with osimertinib or lazertinib. Pacientes con cáncer de pulmón de células no pequeñas:• Con mutación en un gen llamado EGFR• Se ha propagado a otras partes del cuerpo durante/ después del tratamiento con osimertinib o lazertinib, Diseases [C] - Cancer [C04] | | | | |
| Terminated | 2 | 648 | Europe, Canada, US, RoW | Poziotinib | Spectrum Pharmaceuticals, Inc | NSCLC | 04/23 | 04/23 | | |
|
|
|
|
|
|
|
|
| Terminated | 2 | 5 | RoW | osimertinib, AZD9291, Tagrisso | AstraZeneca | Lung Cancer | 03/23 | 03/23 | | |
ORBITAL, NCT04233021: Study of Osimertinib in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation |
|
|
| Active, not recruiting | 2 | 57 | Europe | Osimertinib | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer Metastatic, Leptomeningeal Metastasis, Brain Metastases, EGFR Activating Mutation | 03/23 | 02/24 | | |
| Active, not recruiting | 2 | 155 | Europe, RoW | Osimertinib, Tagrisso, Bevacizumab, Avastin | ETOP IBCSG Partners Foundation, AstraZeneca, Hoffmann-La Roche | Non Small Cell Lung Cancer Metastatic | 05/23 | 05/23 | | |
|
| Active, not recruiting | 2 | 140 | Europe, Japan, US, RoW | Tepotinib, Osimertinib, Tagrisso® | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Non-small Cell Lung Cancer | 05/23 | 05/24 | | |
TREM, NCT02504346 / 2015-000307-10: AZD9291, an Irreversible EGFR-TKI, in Relapsed EGFR-mutated Non-small Cell Lung Cancer Patients Previously Treated With an EGFR-TKI, Coupled to Extensive Translational Studies |
|
|
| Active, not recruiting | 2 | 200 | Europe | AZD9291 | Oslo University Hospital, AstraZeneca | Lung Cancer, Targeted Therapy | 06/23 | 06/23 | | |